Pre-vaccine plasma levels of soluble inflammatory indices negatively predict responses to HAV, HBV, and tetanus vaccines in HCV and HIV infection
Chronic hepatitis C virus (HCV) and HIV infections are associated with impaired responses to neo-antigens contained in hepatitis A virus (HAV)/hepatitis B virus (HBV) vaccines, yet responsible mechanisms are unclear. ACTG 5232 and CFAR0910 were clinical trials where pre-vaccine levels of plasma IP10...
Gespeichert in:
| Veröffentlicht in: | Vaccine 2018-01, Vol.36 (4), p.453-460 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 460 |
|---|---|
| container_issue | 4 |
| container_start_page | 453 |
| container_title | Vaccine |
| container_volume | 36 |
| creator | Shive, Carey L. Judge, Chelsey J. Clagett, Brian Kalayjian, Robert C. Osborn, Melissa Sherman, Kenneth E. Fichtenbaum, Carl Gandhi, Rajesh T. Kang, Minhee Popkin, Daniel L. Sieg, Scott F. Lederman, Michael M. Rodriguez, Benigno Anthony, Donald D. |
| description | Chronic hepatitis C virus (HCV) and HIV infections are associated with impaired responses to neo-antigens contained in hepatitis A virus (HAV)/hepatitis B virus (HBV) vaccines, yet responsible mechanisms are unclear.
ACTG 5232 and CFAR0910 were clinical trials where pre-vaccine levels of plasma IP10, IL-6, sCD163 and sCD14 were measured in viremic HCV- (n = 15) or HIV-infected participants (n = 24) and uninfected controls (n = 10). Accelerated dosing HAV/HBV vaccine and tetanus booster were administered and antibody response was measured at 0, 1, 3, 8, and 24 weeks.
Pre-vaccine plasma IP10, IL-6, and sCD14 levels were elevated in both HCV and HIV-infected participants, while sCD163 was also elevated in HCV-infected participants. Pre-immunization tetanus antibody levels were lower in HIV-infected than in uninfected participants, while vaccine induced antibody responses were intact in HCV and HIV-infected participants. After HAV/HBV vaccination, HCV and HIV-infected participants had lower and less durable HAV and HBV antibody responses than uninfected controls.
Among HCV-infected participants, pre-vaccine plasma IP10, IL-6, sCD14, and sCD163 levels inversely correlated with HAV, HBV and tetanus antibody responses after vaccine. Low HAV/HBV vaccine responses in HIV-infected participants prohibited assessment of immune correlates.
During HCV and HIV infection markers of systemic inflammation reflect immune dysfunction as demonstrated by poor response to HAV/HBV neo-antigen vaccine. |
| doi_str_mv | 10.1016/j.vaccine.2017.12.018 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5767517</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X17317619</els_id><sourcerecordid>2007538412</sourcerecordid><originalsourceid>FETCH-LOGICAL-c495t-8996cba32129279a08f2d8161707a180f719f9ea2fbc752c22f62f93bb32dd203</originalsourceid><addsrcrecordid>eNqFkc-O1DAMxisEYoeFRwBF4sKBljj9k_QCWkZAV1oJDjDiFqWpu2TUJiVpR5rH4I3JMGUFXLgkiv3z59hfkjwFmgGF6tU-OyitjcWMUeAZsIyCuJdsQPA8ZSWI-8mGsqpIC6BfL5JHIewppWUO9cPkgtWsLERBN8mPTx7TVYlMgwqjIgMecAjE9SS4YWkHJMb2gxpHNTt_jI_OaAzE4q2aTUSPZPIYYzPxGCZnQ0zOjjRXu5ekeRsPZTsy46zsEsjaK0QZ0mx3v3LN9e7UAvVsnH2cPOjVEPDJel8mX96_-7xt0puPH663VzepLupyTkVdV7pVOYM4DK8VFT3rBFTAKVcgaM-h7mtUrG81L5lmrK9YX-dtm7OuYzS_TF6fdaelHbHTaGevBjl5Myp_lE4Z-XfGmm_y1h1kySteAo8CL1YB774vGGY5mqBxGJRFtwQJNRec8SKHiD7_B927xds4nmSU8jIXBbBIlWdKexeCx_7uM0DlyXS5l-v65Ml0CUxG02Pdsz8nuav67XIE3pyBaCseDHoZtEGro2k-Ll12zvynxU9zacGx</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2007538412</pqid></control><display><type>article</type><title>Pre-vaccine plasma levels of soluble inflammatory indices negatively predict responses to HAV, HBV, and tetanus vaccines in HCV and HIV infection</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><source>ProQuest Central UK/Ireland</source><creator>Shive, Carey L. ; Judge, Chelsey J. ; Clagett, Brian ; Kalayjian, Robert C. ; Osborn, Melissa ; Sherman, Kenneth E. ; Fichtenbaum, Carl ; Gandhi, Rajesh T. ; Kang, Minhee ; Popkin, Daniel L. ; Sieg, Scott F. ; Lederman, Michael M. ; Rodriguez, Benigno ; Anthony, Donald D.</creator><creatorcontrib>Shive, Carey L. ; Judge, Chelsey J. ; Clagett, Brian ; Kalayjian, Robert C. ; Osborn, Melissa ; Sherman, Kenneth E. ; Fichtenbaum, Carl ; Gandhi, Rajesh T. ; Kang, Minhee ; Popkin, Daniel L. ; Sieg, Scott F. ; Lederman, Michael M. ; Rodriguez, Benigno ; Anthony, Donald D.</creatorcontrib><description>Chronic hepatitis C virus (HCV) and HIV infections are associated with impaired responses to neo-antigens contained in hepatitis A virus (HAV)/hepatitis B virus (HBV) vaccines, yet responsible mechanisms are unclear.
ACTG 5232 and CFAR0910 were clinical trials where pre-vaccine levels of plasma IP10, IL-6, sCD163 and sCD14 were measured in viremic HCV- (n = 15) or HIV-infected participants (n = 24) and uninfected controls (n = 10). Accelerated dosing HAV/HBV vaccine and tetanus booster were administered and antibody response was measured at 0, 1, 3, 8, and 24 weeks.
Pre-vaccine plasma IP10, IL-6, and sCD14 levels were elevated in both HCV and HIV-infected participants, while sCD163 was also elevated in HCV-infected participants. Pre-immunization tetanus antibody levels were lower in HIV-infected than in uninfected participants, while vaccine induced antibody responses were intact in HCV and HIV-infected participants. After HAV/HBV vaccination, HCV and HIV-infected participants had lower and less durable HAV and HBV antibody responses than uninfected controls.
Among HCV-infected participants, pre-vaccine plasma IP10, IL-6, sCD14, and sCD163 levels inversely correlated with HAV, HBV and tetanus antibody responses after vaccine. Low HAV/HBV vaccine responses in HIV-infected participants prohibited assessment of immune correlates.
During HCV and HIV infection markers of systemic inflammation reflect immune dysfunction as demonstrated by poor response to HAV/HBV neo-antigen vaccine.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2017.12.018</identifier><identifier>PMID: 29254840</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Acquired immune deficiency syndrome ; Adult ; AIDS ; Antibodies, Viral - blood ; Antibodies, Viral - immunology ; Antibody response ; Antigens ; Biomarkers ; CD4 Lymphocyte Count ; Cellular immunity ; Chronic infection ; Clinical trials ; Cytokines - blood ; Female ; Hepatitis ; Hepatitis A ; Hepatitis A Vaccines - immunology ; Hepatitis B ; Hepatitis B Vaccines - immunology ; Hepatitis C ; Hepatitis C - blood ; Hepatitis C - epidemiology ; Hepatitis C - immunology ; HIV ; HIV Infections - blood ; HIV Infections - epidemiology ; HIV Infections - immunology ; Human immunodeficiency virus ; Humans ; Immunity ; Immunization ; Inflammation ; Inflammation Mediators - blood ; Interleukin 6 ; Male ; Medical research ; Middle Aged ; Mortality ; Plasma levels ; Public health ; Rodents ; T cell ; Tetanus ; Tetanus Toxoid - immunology ; Vaccines ; Viruses ; Young Adult</subject><ispartof>Vaccine, 2018-01, Vol.36 (4), p.453-460</ispartof><rights>2017</rights><rights>Published by Elsevier Ltd.</rights><rights>Copyright Elsevier Limited Jan 25, 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c495t-8996cba32129279a08f2d8161707a180f719f9ea2fbc752c22f62f93bb32dd203</citedby><cites>FETCH-LOGICAL-c495t-8996cba32129279a08f2d8161707a180f719f9ea2fbc752c22f62f93bb32dd203</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/2007538412?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>230,314,780,784,885,3550,27924,27925,45995,64385,64387,64389,72469</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29254840$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Shive, Carey L.</creatorcontrib><creatorcontrib>Judge, Chelsey J.</creatorcontrib><creatorcontrib>Clagett, Brian</creatorcontrib><creatorcontrib>Kalayjian, Robert C.</creatorcontrib><creatorcontrib>Osborn, Melissa</creatorcontrib><creatorcontrib>Sherman, Kenneth E.</creatorcontrib><creatorcontrib>Fichtenbaum, Carl</creatorcontrib><creatorcontrib>Gandhi, Rajesh T.</creatorcontrib><creatorcontrib>Kang, Minhee</creatorcontrib><creatorcontrib>Popkin, Daniel L.</creatorcontrib><creatorcontrib>Sieg, Scott F.</creatorcontrib><creatorcontrib>Lederman, Michael M.</creatorcontrib><creatorcontrib>Rodriguez, Benigno</creatorcontrib><creatorcontrib>Anthony, Donald D.</creatorcontrib><title>Pre-vaccine plasma levels of soluble inflammatory indices negatively predict responses to HAV, HBV, and tetanus vaccines in HCV and HIV infection</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>Chronic hepatitis C virus (HCV) and HIV infections are associated with impaired responses to neo-antigens contained in hepatitis A virus (HAV)/hepatitis B virus (HBV) vaccines, yet responsible mechanisms are unclear.
ACTG 5232 and CFAR0910 were clinical trials where pre-vaccine levels of plasma IP10, IL-6, sCD163 and sCD14 were measured in viremic HCV- (n = 15) or HIV-infected participants (n = 24) and uninfected controls (n = 10). Accelerated dosing HAV/HBV vaccine and tetanus booster were administered and antibody response was measured at 0, 1, 3, 8, and 24 weeks.
Pre-vaccine plasma IP10, IL-6, and sCD14 levels were elevated in both HCV and HIV-infected participants, while sCD163 was also elevated in HCV-infected participants. Pre-immunization tetanus antibody levels were lower in HIV-infected than in uninfected participants, while vaccine induced antibody responses were intact in HCV and HIV-infected participants. After HAV/HBV vaccination, HCV and HIV-infected participants had lower and less durable HAV and HBV antibody responses than uninfected controls.
Among HCV-infected participants, pre-vaccine plasma IP10, IL-6, sCD14, and sCD163 levels inversely correlated with HAV, HBV and tetanus antibody responses after vaccine. Low HAV/HBV vaccine responses in HIV-infected participants prohibited assessment of immune correlates.
During HCV and HIV infection markers of systemic inflammation reflect immune dysfunction as demonstrated by poor response to HAV/HBV neo-antigen vaccine.</description><subject>Acquired immune deficiency syndrome</subject><subject>Adult</subject><subject>AIDS</subject><subject>Antibodies, Viral - blood</subject><subject>Antibodies, Viral - immunology</subject><subject>Antibody response</subject><subject>Antigens</subject><subject>Biomarkers</subject><subject>CD4 Lymphocyte Count</subject><subject>Cellular immunity</subject><subject>Chronic infection</subject><subject>Clinical trials</subject><subject>Cytokines - blood</subject><subject>Female</subject><subject>Hepatitis</subject><subject>Hepatitis A</subject><subject>Hepatitis A Vaccines - immunology</subject><subject>Hepatitis B</subject><subject>Hepatitis B Vaccines - immunology</subject><subject>Hepatitis C</subject><subject>Hepatitis C - blood</subject><subject>Hepatitis C - epidemiology</subject><subject>Hepatitis C - immunology</subject><subject>HIV</subject><subject>HIV Infections - blood</subject><subject>HIV Infections - epidemiology</subject><subject>HIV Infections - immunology</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Immunity</subject><subject>Immunization</subject><subject>Inflammation</subject><subject>Inflammation Mediators - blood</subject><subject>Interleukin 6</subject><subject>Male</subject><subject>Medical research</subject><subject>Middle Aged</subject><subject>Mortality</subject><subject>Plasma levels</subject><subject>Public health</subject><subject>Rodents</subject><subject>T cell</subject><subject>Tetanus</subject><subject>Tetanus Toxoid - immunology</subject><subject>Vaccines</subject><subject>Viruses</subject><subject>Young Adult</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkc-O1DAMxisEYoeFRwBF4sKBljj9k_QCWkZAV1oJDjDiFqWpu2TUJiVpR5rH4I3JMGUFXLgkiv3z59hfkjwFmgGF6tU-OyitjcWMUeAZsIyCuJdsQPA8ZSWI-8mGsqpIC6BfL5JHIewppWUO9cPkgtWsLERBN8mPTx7TVYlMgwqjIgMecAjE9SS4YWkHJMb2gxpHNTt_jI_OaAzE4q2aTUSPZPIYYzPxGCZnQ0zOjjRXu5ekeRsPZTsy46zsEsjaK0QZ0mx3v3LN9e7UAvVsnH2cPOjVEPDJel8mX96_-7xt0puPH663VzepLupyTkVdV7pVOYM4DK8VFT3rBFTAKVcgaM-h7mtUrG81L5lmrK9YX-dtm7OuYzS_TF6fdaelHbHTaGevBjl5Myp_lE4Z-XfGmm_y1h1kySteAo8CL1YB774vGGY5mqBxGJRFtwQJNRec8SKHiD7_B927xds4nmSU8jIXBbBIlWdKexeCx_7uM0DlyXS5l-v65Ml0CUxG02Pdsz8nuav67XIE3pyBaCseDHoZtEGro2k-Ll12zvynxU9zacGx</recordid><startdate>20180125</startdate><enddate>20180125</enddate><creator>Shive, Carey L.</creator><creator>Judge, Chelsey J.</creator><creator>Clagett, Brian</creator><creator>Kalayjian, Robert C.</creator><creator>Osborn, Melissa</creator><creator>Sherman, Kenneth E.</creator><creator>Fichtenbaum, Carl</creator><creator>Gandhi, Rajesh T.</creator><creator>Kang, Minhee</creator><creator>Popkin, Daniel L.</creator><creator>Sieg, Scott F.</creator><creator>Lederman, Michael M.</creator><creator>Rodriguez, Benigno</creator><creator>Anthony, Donald D.</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20180125</creationdate><title>Pre-vaccine plasma levels of soluble inflammatory indices negatively predict responses to HAV, HBV, and tetanus vaccines in HCV and HIV infection</title><author>Shive, Carey L. ; Judge, Chelsey J. ; Clagett, Brian ; Kalayjian, Robert C. ; Osborn, Melissa ; Sherman, Kenneth E. ; Fichtenbaum, Carl ; Gandhi, Rajesh T. ; Kang, Minhee ; Popkin, Daniel L. ; Sieg, Scott F. ; Lederman, Michael M. ; Rodriguez, Benigno ; Anthony, Donald D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c495t-8996cba32129279a08f2d8161707a180f719f9ea2fbc752c22f62f93bb32dd203</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Acquired immune deficiency syndrome</topic><topic>Adult</topic><topic>AIDS</topic><topic>Antibodies, Viral - blood</topic><topic>Antibodies, Viral - immunology</topic><topic>Antibody response</topic><topic>Antigens</topic><topic>Biomarkers</topic><topic>CD4 Lymphocyte Count</topic><topic>Cellular immunity</topic><topic>Chronic infection</topic><topic>Clinical trials</topic><topic>Cytokines - blood</topic><topic>Female</topic><topic>Hepatitis</topic><topic>Hepatitis A</topic><topic>Hepatitis A Vaccines - immunology</topic><topic>Hepatitis B</topic><topic>Hepatitis B Vaccines - immunology</topic><topic>Hepatitis C</topic><topic>Hepatitis C - blood</topic><topic>Hepatitis C - epidemiology</topic><topic>Hepatitis C - immunology</topic><topic>HIV</topic><topic>HIV Infections - blood</topic><topic>HIV Infections - epidemiology</topic><topic>HIV Infections - immunology</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Immunity</topic><topic>Immunization</topic><topic>Inflammation</topic><topic>Inflammation Mediators - blood</topic><topic>Interleukin 6</topic><topic>Male</topic><topic>Medical research</topic><topic>Middle Aged</topic><topic>Mortality</topic><topic>Plasma levels</topic><topic>Public health</topic><topic>Rodents</topic><topic>T cell</topic><topic>Tetanus</topic><topic>Tetanus Toxoid - immunology</topic><topic>Vaccines</topic><topic>Viruses</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shive, Carey L.</creatorcontrib><creatorcontrib>Judge, Chelsey J.</creatorcontrib><creatorcontrib>Clagett, Brian</creatorcontrib><creatorcontrib>Kalayjian, Robert C.</creatorcontrib><creatorcontrib>Osborn, Melissa</creatorcontrib><creatorcontrib>Sherman, Kenneth E.</creatorcontrib><creatorcontrib>Fichtenbaum, Carl</creatorcontrib><creatorcontrib>Gandhi, Rajesh T.</creatorcontrib><creatorcontrib>Kang, Minhee</creatorcontrib><creatorcontrib>Popkin, Daniel L.</creatorcontrib><creatorcontrib>Sieg, Scott F.</creatorcontrib><creatorcontrib>Lederman, Michael M.</creatorcontrib><creatorcontrib>Rodriguez, Benigno</creatorcontrib><creatorcontrib>Anthony, Donald D.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shive, Carey L.</au><au>Judge, Chelsey J.</au><au>Clagett, Brian</au><au>Kalayjian, Robert C.</au><au>Osborn, Melissa</au><au>Sherman, Kenneth E.</au><au>Fichtenbaum, Carl</au><au>Gandhi, Rajesh T.</au><au>Kang, Minhee</au><au>Popkin, Daniel L.</au><au>Sieg, Scott F.</au><au>Lederman, Michael M.</au><au>Rodriguez, Benigno</au><au>Anthony, Donald D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pre-vaccine plasma levels of soluble inflammatory indices negatively predict responses to HAV, HBV, and tetanus vaccines in HCV and HIV infection</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2018-01-25</date><risdate>2018</risdate><volume>36</volume><issue>4</issue><spage>453</spage><epage>460</epage><pages>453-460</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><abstract>Chronic hepatitis C virus (HCV) and HIV infections are associated with impaired responses to neo-antigens contained in hepatitis A virus (HAV)/hepatitis B virus (HBV) vaccines, yet responsible mechanisms are unclear.
ACTG 5232 and CFAR0910 were clinical trials where pre-vaccine levels of plasma IP10, IL-6, sCD163 and sCD14 were measured in viremic HCV- (n = 15) or HIV-infected participants (n = 24) and uninfected controls (n = 10). Accelerated dosing HAV/HBV vaccine and tetanus booster were administered and antibody response was measured at 0, 1, 3, 8, and 24 weeks.
Pre-vaccine plasma IP10, IL-6, and sCD14 levels were elevated in both HCV and HIV-infected participants, while sCD163 was also elevated in HCV-infected participants. Pre-immunization tetanus antibody levels were lower in HIV-infected than in uninfected participants, while vaccine induced antibody responses were intact in HCV and HIV-infected participants. After HAV/HBV vaccination, HCV and HIV-infected participants had lower and less durable HAV and HBV antibody responses than uninfected controls.
Among HCV-infected participants, pre-vaccine plasma IP10, IL-6, sCD14, and sCD163 levels inversely correlated with HAV, HBV and tetanus antibody responses after vaccine. Low HAV/HBV vaccine responses in HIV-infected participants prohibited assessment of immune correlates.
During HCV and HIV infection markers of systemic inflammation reflect immune dysfunction as demonstrated by poor response to HAV/HBV neo-antigen vaccine.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>29254840</pmid><doi>10.1016/j.vaccine.2017.12.018</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2018-01, Vol.36 (4), p.453-460 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5767517 |
| source | MEDLINE; Access via ScienceDirect (Elsevier); ProQuest Central UK/Ireland |
| subjects | Acquired immune deficiency syndrome Adult AIDS Antibodies, Viral - blood Antibodies, Viral - immunology Antibody response Antigens Biomarkers CD4 Lymphocyte Count Cellular immunity Chronic infection Clinical trials Cytokines - blood Female Hepatitis Hepatitis A Hepatitis A Vaccines - immunology Hepatitis B Hepatitis B Vaccines - immunology Hepatitis C Hepatitis C - blood Hepatitis C - epidemiology Hepatitis C - immunology HIV HIV Infections - blood HIV Infections - epidemiology HIV Infections - immunology Human immunodeficiency virus Humans Immunity Immunization Inflammation Inflammation Mediators - blood Interleukin 6 Male Medical research Middle Aged Mortality Plasma levels Public health Rodents T cell Tetanus Tetanus Toxoid - immunology Vaccines Viruses Young Adult |
| title | Pre-vaccine plasma levels of soluble inflammatory indices negatively predict responses to HAV, HBV, and tetanus vaccines in HCV and HIV infection |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T17%3A18%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pre-vaccine%20plasma%20levels%20of%20soluble%20inflammatory%20indices%20negatively%20predict%20responses%20to%20HAV,%20HBV,%20and%20tetanus%20vaccines%20in%20HCV%20and%20HIV%20infection&rft.jtitle=Vaccine&rft.au=Shive,%20Carey%20L.&rft.date=2018-01-25&rft.volume=36&rft.issue=4&rft.spage=453&rft.epage=460&rft.pages=453-460&rft.issn=0264-410X&rft.eissn=1873-2518&rft_id=info:doi/10.1016/j.vaccine.2017.12.018&rft_dat=%3Cproquest_pubme%3E2007538412%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2007538412&rft_id=info:pmid/29254840&rft_els_id=S0264410X17317619&rfr_iscdi=true |